Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 112 results found since Jan 2013.

Abstract 068: Role for the Rho-GAP Graf3 in the Pathogenesis of Human Hypertension Session Title: Concurrent XIV B: Vascular Biology I
Activation of RhoA in vascular smooth muscle cells (SMC) has been linked to vasoconstrictor-induced hypertension (HTN), but the relevance of this pathway to human disease was undetermined. We identified GRAF3 as a RhoA-GAP expressed specifically in SMC in mice and humans and reported that global GRAF3-deficient mice exhibited significant basal HTN (+ 25 mm Hg) that was fully reversed by treatment with a Rho-kinase inhibitor (Nature Comm. 2013;4:2910). Importantly, we recently created a tamoxifen inducible SMC-GRAF3 re-expression model which resulted in a near complete reversal of MAP (from 123 mmHg to 95 mm Hg), indicating...
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Bai, X., Mangum, K., Mack, C., Taylor, J. M. Tags: Session Title: Concurrent XIV B: Vascular Biology I Source Type: research

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients
Abstract Aromatase inhibitors (AI), either alone or together with chemotherapy, have become the standard adjuvant treatment for postmenopausal, estrogen receptor-positive (ER+) breast cancer. Although AIs improve overall survival, resistance is still a major clinical problem, thus additional biomarkers predictive of outcome of ER+ breast cancer patients treated with AIs are needed. Global gene expression analysis was performed on ER+ primary breast cancers from patients treated with adjuvant AI monotherapy; half experienced recurrence (median follow-up 6.7 years). Gene expression alterations were validated by qR...
Source: Breast Cancer Research and Treatment - November 19, 2015 Category: Cancer & Oncology Source Type: research

Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells
Abstract Development of new therapeutic strategies is becoming increasingly important to overcome tamoxifen resistance. Recently, much interest has been focused on anti-tumor effects of metformin commonly used to treat type II diabetes. Increased protein expression and signaling of epidermal growth factor receptor (EGFR) family is a possible mechanism involved in tamoxifen resistance. Since HER2/HER3 heterodimers are able to induce strong downstream signaling and activate various biological responses such as cellular proliferation and growth, we investigated the anti-cancer effect of metformin by inhibition of sig...
Source: Tumor Biology - November 18, 2015 Category: Cancer & Oncology Source Type: research

Abstract C150: High expression of SNAI2 is associated with the emergence of a highly motile fulvestrant-resistant phenotype and is an indicator of poor response to endocrine treatment in estrogen receptor-positive metastatic breast cancer
Endocrine resistance is a major clinical problem and is associated with the acquisition of aggressive tumor spread and invasion. To investigate the association between endocrine resistance and tumor cell migration and invasion, we evaluated a panel of MCF7-based cell line models resistant to either tamoxifen, aromatase inhibitors or fulvestrant. Fulvestrant-resistant cell lines showed a significantly higher migration capacity than the parental fulvestrant-sensitive cell line. Gene expression profiling and data analysis using Ingenuity Pathway Analysis (IPA) of these fulvestrant-resistant/fulvestrant-sensitive cell lines id...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Alves, C. L., Elias, D., Lyng, M., Bak, M., Lykkesfeldt, A. E., Ditzel, H. J. Tags: Target Identification and Validation: Poster Presentations - Proffered Abstracts Source Type: research

Abstract S4-05: Interrogating the landscape of long noncoding RNAs in breast cancer to identify predictors of tamoxifen resistance
Conclusion: In this study, we develop the largest reported compendia of breast cancer lncRNAs. We prioritize BRCAT431 as the top lncRNA upregulated in ER-positive breast cancers, and demonstrate that it confers aggressive oncogenic phenotypes in vitro and in vivo. We identify a novel mechanism by which this lncRNA functions. Our results suggest that by promoting tamoxifen resistance, BRCAT431 increases the clinical risk of recurrence and metastases in breast cancer. Overall, this study supports the rationale for investigating lncRNAs as novel biomarkers and therapeutic targets in breast cancer.Citation Format: Feng FY, Nik...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Feng, F., Niknafs, Y., Han, S., Ma, T., Speers, C., Malik, R., Evans, J., Zhang, C., Pierce, L., Hayes, D., Rae, J., Chinnaiyan, A. Tags: General Session Abstracts Source Type: research

Abstract P1-05-06: Essential role of notch-4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer
In conclusion, inhibition of Notch signaling may have efficacy in the treatment of breast cancer metastasis.Citation Format: Bui QT, Kang KW. Essential role of notch-4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-05-06.
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Bui, Q., Kang, K. Tags: Poster Session Abstracts Source Type: research

Abstract P3-04-02: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are estrogen receptor (ER)-positive, however, endocrine response and estrogen signaling are not well understood in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than invasive ductal carcinoma (IDC) patients, and that ILC patients may not benefit from adjuvant tamoxifen. Based on these observations, we hypothesize that ER regulates unique signaling pathways in ILC cells that control growth and endocrine response.To identi...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Sikora, M., Oesterreich, S. Tags: Poster Session Abstracts Source Type: research

Abstract P5-04-17: From transcriptome meta-analysis to targeted therapies in triple negative breast cancer
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that urgently requires the identification and approval of novel targeted therapies. Even for breast cancer subtypes that have approved targeted therapies such as tamoxifen in ER+ and herceptin in HER2+ patients, there are a proportion of patients that do not respond to these therapies or develop resistance and succumb to metastatic recurrence. Thus, there is a clinical need to identify patients who do not benefit from current standard therapies and developing new strategies for therapy for non-responsive patients across all breast cancer subtypes.We hypothe...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Rozali, E., Al-Ejeh, F. Tags: Poster Session Abstracts Source Type: research

Oxidative stress and glyoxalase-1 activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen-resistant derivative
Conclusions Dicarbonyl toxicity was mediated by oxidative stress and GLO-1 activity determines aldehyde toxicity in tamoxifen resistant cells. General Significance. Glyoxalases might be predictive biomarkers for tamoxifen resistance and a putative target for the treatment of tamoxifen resistant breast cancer patients. Graphical abstract
Source: Biochimica et Biophysica Acta (BBA) General Subjects - March 12, 2016 Category: Biochemistry Source Type: research

Oxidative stress and glyoxalase-1 activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative.
CONCLUSIONS: Dicarbonyl toxicity was mediated by oxidative stress and GLO-1 activity determines aldehyde toxicity in tamoxifen resistant cells. GENERAL SIGNIFICANCE: Glyoxalases might be predictive biomarkers for tamoxifen resistance and a putative target for the treatment of tamoxifen resistant breast cancer patients. PMID: 26971627 [PubMed - as supplied by publisher]
Source: Biochimica et Biophysica Acta - March 10, 2016 Category: Biochemistry Authors: Nass N, Sel S, Ignatov A, Roessner A, Kalinski T Tags: Biochim Biophys Acta Source Type: research

Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative
Conclusions Dicarbonyl toxicity was mediated by oxidative stress and GLO1 activity determines aldehyde toxicity in tamoxifen resistant cells. General Significance Glyoxalases might be predictive biomarkers for tamoxifen resistance and a putative target for the treatment of tamoxifen resistant breast cancer patients. Graphical abstract
Source: Biochimica et Biophysica Acta (BBA) General Subjects - March 22, 2016 Category: Biochemistry Source Type: research

San Huang Decoction downregulates Aurora kinase A to inhibit breast cancer cell growth and enhance chemosenstivity to anti-tumor drugs
Publication date: Available online 18 May 2016 Source:Pathology - Research and Practice Author(s): Yanlei Xu, Xu Chen, Xiyan Chen, Weihe Bian, Chang Yao, Xiaoqing Zhang, Xiaoshu Zhu, Jiajing Chen, Xiaozhou Ye Our study aimed to explore whether San Huang Decoction (SHD) inhibited the development of breast cancer by regulating Aurora A. Human breast cancer cell lines MCF-7 and MDA-MB-231 were cultured and SHD extract was prepared. Cell growth assay and apoptosis analysis were respectively performed to detect the effects of SHD on breast cancer cells. In addition, the effects of SHD on the expression of Aurora A an...
Source: Pathology Research and Practice - May 17, 2016 Category: Pathology Source Type: research

Tamoxifen-induced cytotoxicity in breast cancer cells is mediated by glucose-regulated protein 78 (GRP78) via AKT (Thr308) regulation.
Abstract Glucose regulated protein 78 (GRP78) has recently been suggested to be associated with drug resistance in breast cancer patients. However, the precise role of GRP78 in drug resistance and the involved signaling pathways are not clearly understood. In the present study, we show that among a panel of drugs, namely Paclitaxel (TAX), Doxorubicin (DOX), 5-fluorouracil (5-FU), UCN-01 and Tamoxifen (TAM) used, TAM alone up-regulated the expression of GRP78 significantly and induced apoptosis in MCF-7 and MDA-MB-231 cells. Interestingly, inhibition of GRP78 by a specific pharmacological inhibitor, VER-155008 augm...
Source: The International Journal of Biochemistry and Cell Biology - May 31, 2016 Category: Biochemistry Authors: Pujari R, Jose J, Bhavnani V, Kumar N, Shastry P, Pal JK Tags: Int J Biochem Cell Biol Source Type: research

SIRT3 Silencing Sensitizes Breast Cancer Cells to Cytotoxic Treatments through an Increment in ROS Production
In conclusion, SIRT3 could be a therapeutic target for breast cancer, improving the effectiveness of CDDP and TAM treatments. This article is protected by copyright. All rights reserved
Source: Journal of Cellular Biochemistry - July 16, 2016 Category: Biochemistry Authors: Margalida Torrens‐Mas, Daniel Gabriel Pons, Jorge Sastre‐Serra, Jordi Oliver, Pilar Roca Tags: Article Source Type: research

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
Authors: Joshi T, Elias D, Stenvang J, Alves CL, Teng F, Lyng MB, Lykkesfeldt AE, Brünner N, Wang J, Gupta R, Workman CT, Ditzel HJ Abstract Tamoxifen is an effective anti-estrogen treatment for patients with estrogen receptor-positive (ER+) breast cancer, however, tamoxifen resistance is frequently observed. To elucidate the underlying molecular mechanisms of tamoxifen resistance, we performed a systematic analysis of miRNA-mediated gene regulation in three clinically-relevant tamoxifen-resistant breast cancer cell lines (TamRs) compared to their parental tamoxifen-sensitive cell line. Alterations in the expressi...
Source: Oncotarget - August 18, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research